[Systemic mastocytosis].
Systemic mastocytosis is characterized by abnormal mast cell proliferation in different organs. The 2001 consensus classification distinguishes in separate categories indolent systemic mastocytosis, systemic mastocytosis with concomitant blood disease, aggressive systemic mastocytosis and mast cell leukemia. Clinical manifestations are caused by tissue infiltration by proliferating mastocytes and by release of mediators. The principal organs affected are the skin, bones, digestive tract, liver, spleen and lymph nodes. Diagnosis of mastocytosis is based on appropriate stains (Giemsa, toluidine blue) and immunophenotype features (tryptase, CD117, also known as c-KIT and stem cell factor receptor). Serum tryptase levels reflect the total mast cell burden. Treatment must prevent release of mast cell mediators (histamine antagonists, cromolyn sodium, corticosteroids, or leukotriene-receptor inhibitors), limit bone involvement (bisphosphonates) and reduce the number of circulating mast cells (interferon, cladribine, or tyrosine kinase inhibitors). Enhanced understanding of the pathogenic mechanisms (mutation of c-kit and platelet-derived growth factor receptor alpha has led to the development of targeted treatments, including new inhibitors of tyrosine kinase and of nuclear factor Kappa B.
Fain
O
O
Service de médecine interne, Hôpital Jean Verdier (AP-HP), Université Paris XIII, Bondy. olivier.fain@jvr.ap-hop-paris.fr
Stirnemann
J
J
Eclache
V
V
Barete
S
S
Casassus
P
P
Hermine
O
O
Lorholary
O
O
D001549:Benzamides; D015415:Biomarkers; D001842:Bone and Bones / Q000473:pathology; D002454:Cell Differentiation; D002455:Cell Division; D017338:Cladribine / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D005483:Flushing / Q000209:etiology; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006636:Histamine Release / Q000187:drug effects; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000627:therapeutic use; D020024:Leukotriene Antagonists / Q000627:therapeutic use; D008407:Mast Cells / Q000187:drug effects / Q000378:metabolism; D034721:Mastocytosis, Systemic / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D015514:Oncogene Proteins, Fusion; D010879:Piperazines / Q000627:therapeutic use; D011379:Prognosis; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics / Q000502:physiology; D011743:Pyrimidines / Q000627:therapeutic use; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics / Q000502:physiology; D012697:Serine Endopeptidases / Q000097:blood; D019089:Stem Cell Factor / Q000502:physiology; D013610:Tachycardia / Q000209:etiology; D053802:Tryptases; D039221:mRNA Cleavage and Polyadenylation Factors / Q000235:genetics / Q000502:physiology
D001549:Benzamides; D015415:Biomarkers; D004164:Diphosphonates; D006634:Histamine H1 Antagonists; D016898:Interferon-alpha; D020024:Leukotriene Antagonists; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D019089:Stem Cell Factor; D039221:mRNA Cleavage and Polyadenylation Factors; D017338:Cladribine; D000068877:Imatinib Mesylate; C479819:FIP1L1-PDGFRA fusion protein, human; D019009:Proto-Oncogene Proteins c-kit; D020796:Receptor, Platelet-Derived Growth Factor alpha; D012697:Serine Endopeptidases; D053802:Tryptases